In8bio, Inc. ( (INAB) ) has released its Q4 earnings. Here is a breakdown of the information In8bio, Inc. presented to its investors.
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell-based immunotherapies for cancer, with a unique approach that leverages the specialized properties of these cells to target diseased tissues.
In its latest earnings report, IN8bio highlighted significant advancements in its clinical programs, particularly in treating high-risk Acute Myeloid Leukemia (AML) and glioblastoma, while also expanding its pipeline with the novel INB-600 platform targeting CD19 for oncology and autoimmune diseases.
The company reported ongoing success in its Phase 1 and Phase 2 clinical trials, with 100% of treated AML patients remaining relapse-free, and promising results in glioblastoma treatment. Financially, IN8bio managed to maintain a stable cash position to support its operations into 2026, despite a net loss of $30.4 million for the year. The company also raised $16.6 million through equity offerings to extend its cash runway.
Looking ahead, IN8bio plans to accelerate patient enrollment in its clinical trials and advance its INB-600 platform towards clinical development, while exploring partnership opportunities to enhance its strategic initiatives. The company remains focused on driving innovation and delivering value to patients and stakeholders.